Non-melanoma skin cancer: Carcinogenesis and chemoprevention

Pathology

Volumn 45, Issue 3, 2013, Pages 331-341

  Chen, Andrew C ^a,b   Halliday, Gary M ^a,b   Damian, Diona L ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

Actinic keratosis; Basal cell carcinoma; Nicotinamide; Squamous cell carcinoma; Ultraviolet radiation

Indexed keywords

EID: 84879675880     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835f515c     Document Type: Article

References (184)

1. Australian Institute of Health and Welfare (AIHW) and Cancer Australia. Non-melanoma Skin Cancer: General Practice Consultations, Hospitalisation and Mortality. Canberra: AIHW, 2008.
2. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries. Cancer in Australia: An Overview. Canberra: AIHW, 2010.
3. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455-64.
4. Strom S. Epidemiology of basal and squamous cell carcinomas of the skin. In: Weber RS, Miller MJ, Goepfert H, editors. Basal and Squamous Cell Skin Cancers of the Head and Neck. Baltimore: Williams and Wilkins, 1996.
5. Gloster HM Jr, Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996; 22: 217-26.
6. National Cancer Control Initiative (NCCI). The 2002 National Non- Melanoma Skin Cancer Survey - A Report by the NCCI Non-melanoma Skin Cancer Working Group. Melbourne: NCCI, 2003.
7. Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006; 184: 6-10.
8. Fransen M, Karahalio A, Sharma N, English DR, Giles GG, Sinclair RD. Non-melanoma skin cancer in Australia. Med J Aust 2012; 197: 565-8.
9. Telfer NR, Colver GB, Morton CA. British Association of D. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
10. Stockfleth E, Sterry W. New treatment modalities for basal cell carcinoma. Recent Results Cancer Res 2002; 160: 259-68.
11. Epstein E, Epstein NN, Bragg K, Linden G. Metastases from squamous cell carcinomas of the skin. Arch Dermatol 1968; 97: 245-51.
12. Moller R, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol 1979; 115: 703-5.
13. Mourouzis C, Boynton A, Grant J, et al. Cutaneous head and neck SCCs and risk of nodal metastasis - UK experience. J Craniomaxillofac Surg 2009; 37: 443-7.
14. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344: 975-83.
15. Cox NH, Eedy DJ, Morton CA, Therapy G. Audit Subcommittee BAoD. Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol 2007; 156: 11-21.
16. Rehman I, Takata M, Wu YY, Rees JL. Genetic change in actinic keratoses. Oncogene 1996; 12: 2483-90.
17. Quinn AG, Sikkink S, Rees JL. Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Res 1994; 54: 4756-9.
18. Jin Y, Jin C, Salemark L, Wennerberg J, Persson B, Jonsson N. Clonal chromosome abnormalities in premalignant lesions of the skin. Cancer Genet Cytogenet 2002; 136: 48-52.
19. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115: 2523-30.
20. Kushida Y, Miki H, Ohmori M. Loss of heterozygosity in actinic keratosis, squamous cell carcinoma and sun-exposed normal-appearing skin in Japanese: difference between Japanese and Caucasians. Cancer Lett 1999; 140: 169-75.
21. Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 1989; 262: 2097-100.
22. Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997; 133: 735-40.
23. Holme SA, Malinovszky K, Roberts DL. Changing trends in nonmelanoma skin cancer in South Wales, 1988-98. Br J Dermatol 2000; 143: 1224-9.
24. Iversen T, Tretli S. Trends for invasive squamous cell neoplasia of the skin in Norway. Br J Cancer 1999; 81: 528-31.
25. Quinn AG, Sikkink S, Rees JL. Delineation of two distinct deleted regions on chromosome 9 in human non-melanoma skin cancers. Genes Chromosomes Cancer 1994; 11: 222-5.
26. Jin Y, Martins C, Jin C, et al. Nonrandom karyotypic features in squamous cell carcinomas of the skin. Genes Chromosomes Cancer 1999; 26: 295-303.
27. Barnetson RS, Halliday GM. Regression in skin tumours: a common phenomenon. Australas J Dermatol 1997; 38: S63-5.
28. Hurt MA. Keratoacanthoma vs. squamous cell carcinoma in contrast with keratoacanthoma is squamous cell carcinoma. J Cutan Pathol 2004; 31: 291-2; author reply 2-3.
29. Kossard S, Tan K-B, Choy C. Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol 2008; 30: 127-34.
30. Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology 1999; 199: 208-12.
31. Schwartz RA. Keratoacanthoma. J Am Acad Dermatol 1994; 30: 1-19; quiz 20-22.
32. Waring AJ, Takata M, Rehman I, Rees JL. Loss of heterozygosity analysis of keratoacanthoma reveals multiple differences from cutaneous squamous cell carcinoma. Br J Cancer 1996; 73: 649-53.
33. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26: 1657-67.
34. Chisiki M, Kawada A, Akiyama M, et al. Bowen's disease showing spontaneous complete regression associated with apoptosis. Br J Dermatol 1999; 140: 939-44.
35. Nihei N, Hiruma M, Ikeda S, Ogawa H. A case of Bowen's disease showing a clinical tendency toward spontaneous regression. J Dermatol 2004; 31: 569-72.
36. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998; 90: 1278-84.
37. Wehner MR, Shive ML, Chren MM, Han J, Qureshi AA, Linos E. Indoor tanning and non-melanoma skin cancer: systematic review and metaanalysis. BMJ 2012; 345: e5909.
38. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136: 1524-30.
39. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154: 498-504.
40. Hardie IR, Strong RW, Hartley LC, Woodruff PW, Clunie GJ. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery 1980; 87: 177-83.
41. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49: 506-9.
42. Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994; 130: 1018-21.
43. Kraemer KH. Xeroderma pigmentosum. A prototype disease of environmental- genetic interaction. Arch Dermatol 1980; 116: 541-2.
44. Lookingbill DP, Lookingbill GL, Leppard B. Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program. J Am Acad Dermatol 1995; 32: 653-8.
45. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272: 1668-71.
46. Fine J-D, Johnson LB, Weiner M, Stein A, Suchindran C. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin. J Am Acad Dermatol 2004; 50: 563-71.
47. Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res 1993; 3: 395-401.
48. Zigman S, Fowler E, Krause AL. Black light induction of skin tumors in mice. J Invest Dermatol 1976; 67: 723-5.
49. Strickland PT. Photocarcinogenesis by near-ultraviolet (UVA) radiation in Sencar mice. J Invest Dermatol 1986; 87: 272-5.
50. Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: new understanding. Arch Dermatol 1997; 133: 1263-70.
51. Damian DL, Matthews YJ, Phan TA, Halliday GM. An action spectrum for ultraviolet radiation-induced immunosuppression in humans. Br J Dermatol 2011; 164: 657-9.
52. Hussein MR. Ultraviolet radiation and skin cancer: molecular mechanisms. J Cutan Pathol 2005; 32: 191-205.
53. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88: 10124-8.
54. Halliday GM. Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat Res 2005; 571: 107-20.
55. Brash DE. UV mutagenic photoproducts in Escherichia coli and human cells: a molecular genetics perspective on human skin cancer. Photochem Photobiol 1988; 48: 59-66.
56. Nishigori C. Cellular aspects of photocarcinogenesis. Photochem Photobiol Sci 2006; 5: 208-14.
57. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003; 17: 1195-214.
58. Danpure HJ, Tyrrell RM. Oxygen-dependence of near UV (365 NM) lethality and the interaction of near UVand X-rays in two mammalian cell lines. Photochem Photobiol 1976; 23: 171-7.
59. Deliconstantinos G, Villiotou V, Stavrides JC. Alterations of nitric oxide synthase and xanthine oxidase activities of human keratinocytes by ultraviolet B radiation. Potential role for peroxynitrite in skin inflammation. Biochem Pharmacol 1996; 51: 1727-38.
60. Moysan A, Clement-Lacroix P, Michel L, Dubertret L, Morliere P. Effects of ultraviolet A and antioxidant defense in cultured fibroblasts and keratinocytes. Photodermatol Photoimmunol Photomed 1996; 11: 192-7.
61. Pence BC, Naylor MF. Effects of single-dose ultraviolet radiation on skin superoxide dismutase, catalase, and xanthine oxidase in hairless mice. J Invest Dermatol 1990; 95: 213-6.
62. Podda M, Traber MG, Weber C, Yan LJ, Packer L. UV-irradiation depletes antioxidants and causes oxidative damage in a model of human skin. Free Radic Biol Med 1998; 24: 55-65.
63. Deliconstantinos G, Villiotou V, Stavrides JC. Increase of particulate nitric oxide synthase activity and peroxynitrite synthesis in UVB-irradiated keratinocyte membranes. Biochem J 1996; 320: 997-1003.
64. Mowbray M, McLintock S, Weerakoon R, et al. Enzyme-independent NO stores in human skin: quantification and influence of UV radiation. J Invest Dermatol 2009; 129: 834-42.
65. Villiotou V, Deliconstantinos G. Nitric oxide, peroxynitrite and nitrosocompounds formation by ultraviolet A (UVA) irradiated human squamous cell carcinoma: potential role of nitric oxide in cancer prognosis. Anticancer Res 1995; 15: 931-42.
66. Park J, Halliday GM, Surjana D, Damian DL. Nicotinamide prevents ultraviolet radiation-induced cellular energy loss. Photochem Photobiol 2010; 86: 942-8.
67. Balard B, Giacomoni PU. Nicotinamide adenosine dinucleotide level in dimethylsulfate-treated or UV-irradiated mouse epidermis. Mutat Res 1989; 219: 71-9.
68. Carroll RP, Ramsay HM, Fryer AA, Hawley CM, Nicol DL, Harden PN. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am J Kidney Dis 2003; 41: 676-83.
69. Kripke ML. Immunological unresponsiveness induced by ultraviolet radiation. Immunol Rev 1984; 80: 87-102.
70. Damian DL, Halliday GM, Barnetson RS. Broad-spectrum sunscreens provide greater protection against ultraviolet-radiation-induced suppression of contact hypersensitivity to a recall antigen in humans. J Invest Dermatol 1997; 109: 146-51.
71. Damian DL, Halliday GM, Taylor CA, Barnetson RS. Ultraviolet radiation induced suppression of Mantoux reactions in humans. J Invest Dermatol 1998; 110: 824-7.
72. Kelly DA, Young AR, McGregor JM, Seed PT, Potten CS, Walker SL. Sensitivity to sunburn is associated with susceptibility to ultraviolet radiation-induced suppression of cutaneous cell-mediated immunity. J Exp Med 2000; 191: 561-6.
73. Yoshikawa T, Rae V, Bruins-SlotW, Van den Berg JW, Taylor JR, Streilein JW. Susceptibility to effects of UVB radiation on induction of contact hypersensitivity as a risk factor for skin cancer in humans. J Invest Dermatol 1990; 95: 530-6.
74. Kripke ML, Cox PA, Alas LG, Yarosh DB. Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice. Proc Natl Acad Sci USA 1992; 89: 7516-20.
75. Kuchel JM, Barnetson RSC, Halliday GM. Cyclobutane pyrimidine dimer formation is a molecular trigger for solar-simulated ultraviolet radiation-induced suppression of memory immunity in humans. Photochem Photobiol Sci 2005; 4: 577-82.
76. Walterscheid JP, Nghiem DX, Kazimi N, et al. Cis-urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor. Proc Natl Acad Sci USA 2006; 103: 17420-5.
77. Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res 2005; 571: 185-205.
78. Cavanagh LL, Sluyter R, Henderson KG, Barnetson RS, Halliday GM. Epidermal Langerhans' cell induction of immunity against an ultravioletinduced skin tumour. Immunology 1996; 87: 475-80.
79. Dandie GW, Clydesdale GJ, Jacobs I, Muller HK. Effects of UV on the migration and function of epidermal antigen presenting cells. Mutat Res 1998; 422: 147-54.
80. Schwarz A, Noordegraaf M, Maeda A, Torii K, Clausen BE, Schwarz T. Langerhans cells are required for UVR-induced immunosuppression. J Invest Dermatol 2010; 130: 1419-27.
81. Byrne SN, Limon-Flores AY, Ullrich SE. Mast cell migration from the skin to the draining lymph nodes upon ultraviolet irradiation represents a key step in the induction of immune suppression. J Immunol 2008; 180: 4648-55.
82. Hart PH, Grimbaldeston MA, Swift GJ, Jaksic A, Noonan FP, Finlay-Jones JJ. Dermal mast cells determine susceptibility to ultraviolet B-induced systemic suppression of contact hypersensitivity responses in mice. J Exp Med 1998; 187: 2045-53.
83. Rana S, Rogers LJ, Halliday GM. Systemic low-dose UVB inhibits CD8 T cells and skin inflammation by alternative and novel mechanisms. Am J Pathol 2011; 178: 2783-91.
84. Rana S, Byrne SN, MacDonald LJ, Chan CY-Y, Halliday GM. Ultraviolet B suppresses immunity by inhibiting effector and memory T cells. Am J Pathol 2008; 172: 993-1004.
85. Byrne SN, Halliday GM. B cells activated in lymph nodes in response to ultraviolet irradiation or by interleukin-10 inhibit dendritic cell induction of immunity. J Invest Dermatol 2005; 124: 570-8.
86. Matsumura Y, Byrne SN, Nghiem DX, Miyahara Y, Ullrich SE. A role for inflammatory mediators in the induction of immunoregulatory B cells. J Immunol 2006; 177: 4810-7.
87. Schwarz T. Regulatory T cells induced by ultraviolet radiation. Int Arch Allergy Immunol 2005; 137: 187-93.
88. Gorman S, Tan JWY, Yerkovich ST, Finlay-Jones JJ, Hart PH. CD4 T cells in lymph nodes of UVB-irradiated mice suppress immune responses to new antigens both in vitro and in vivo. J Invest Dermatol 2007; 127: 915-24.
89. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000; 1: 521-5.
90. Fukunaga A, Khaskhely NM, Ma Y, et al. Langerhans cells serve as immunoregulatory cells by activating NKT cells. J Immunol 2010; 185: 4633-40.
91. Herzinger T, Funk JO, Hillmer K, Eick D, Wolf DA, Kind P. Ultraviolet B irradiation-induced G2 cell cycle arrest in human keratinocytes by inhibitory phosphorylation of the cdc2 cell cycle kinase. Oncogene 1995; 11: 2151-6.
92. Soehnge H, Ouhtit A, Ananthaswamy ON. Mechanisms of induction of skin cancer by UV radiation. Front Biosci 1997; 2: d538-51.
93. Halliday GM, Bock VL, Moloney FJ, Lyons JG. SWI/SNF: a chromatinremodelling complex with a role in carcinogenesis. Int J Biochem Cell Biol 2009; 41: 725-8.
94. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996; 24: 141-6.
95. Agar NS, Halliday GM, Barnetson RS, Ananthaswamy HN, Wheeler M, Jones AM. The basal layer in human squamous tumors harbors more UVA than UVB fingerprint mutations: a role for UVA in human skin carcinogenesis. Proc Natl Acad Sci USA 2004; 101: 4954-9.
96. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003; 21: 217-28.
97. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994; 85: 23-9.
98. Jonason AS, Kunala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996; 93: 14025-9.
99. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18: 7621-36.
100. Benjamin CL, Melnikova VO, Ananthaswamy HN. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008; 624: 265-82.
101. Trappey A, Fernando A, Gaur R, Raj M, Ouhtit A. The shady side of sunlight: current understanding of the mechanisms underlying UV-induction of skin cancers. Front Biosci 2010; 2: 11-7.
102. Ouhtit A, Muller HK, Davis DW, Ullrich SE, McConkey D, Ananthaswamy HN. Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. Am J Pathol 2000; 156: 201-7.
103. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-6.
104. Tornaletti S, Pfeifer GP. Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science 1994; 263: 1436-8.
105. Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 1993; 90: 4216-20.
106. Deppert W, Gohler T, Koga H, Kim E. Mutant p53: 'gain of function' through perturbation of nuclear structure and function? J Cell Biochem 2000; Suppl 35: 115-22.
107. Villavicencio EH, Walterhouse DO, Iannaccone PM. The sonic hedgehogpatched- gli pathway in human development and disease. Am J Hum Genet 2000; 67: 1047-54.
108. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996; 14: 78-81.
109. Wolter M, Reifenberger J, Sommer C, Ruzicka T, Reifenberger G. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997; 57: 2581-5.
110. Goodsell DS. The molecular perspective: the ras oncogene. Oncologist 1999; 4: 263-4.
111. Ananthaswamy HN, Pierceall WE. Molecular mechanisms of ultraviolet radiation carcinogenesis. Photochem Photobiol 1990; 52: 1119-36.
112. Daya-Grosjean L, Robert C, Drougard C, Suarez H, Sarasin A. High mutation frequency in ras genes of skin tumors isolated from DNA repair deficient xeroderma pigmentosum patients. Cancer Res 1993; 53: 1625-9.
113. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012; 10: 107.
114. Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012; 167: 1153-60.
115. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamouscell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-15.
116. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-21.
117. Botchkarev VA, Gdula MR, Mardaryev AN, Sharov AA, Fessing MY. Epigenetic regulation of gene expression in keratinocytes. J Invest Dermatol 2012; 132: 2505-21.
118. Bock VL, Lyons JG, Huang XXJ, et al. BRM and BRG1 subunits of the SWI/SNF chromatin remodelling complex are downregulated upon progression of benign skin lesions into invasive tumours. Br J Dermatol 2011; 164: 1221-7.
119. Moloney FJ, Lyons JG, Bock VL, Huang XX, Bugeja MJ, Halliday GM. Hotspot mutation of Brahma in non-melanoma skin cancer. J Invest Dermatol 2009; 129: 1012-5.
120. Halliday GM, Zhou Y, Sou PW, et al. The absence of Brm exacerbates photocarcinogenesis. Exp Dermatol 2012; 21: 599-604.
121. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 2007; 107: S2-S5.
122. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4: 46-54.
123. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157-62.
124. Meyer T, Arndt R, Nindl I, Ulrich C, Christophers E, Stockfleth E. Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients. Transpl Int 2003; 16: 146-53.
125. Meyer T, Arndt R, Christophers E, Nindl I, Stockfleth E. Importance of human papillomaviruses for the development of skin cancer. Cancer Detect Prev 2001; 25: 533-47.
126. Pfister H. Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003; 31: 52-6.
127. Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. Arch Dermatol 2012; 148: 939-46.
128. Rollison DE, Iannacone MR, Messina JL, et al. Case-control study of smoking and non-melanoma skin cancer. Cancer Causes Control 2012; 23: 245-54.
129. Khan MMH, Sakauchi F, Sonoda T, Washio M, Mori M. Magnitude of arsenic toxicity in tube-well drinking water in Bangladesh and its adverse effects on human health including cancer: evidence from a review of the literature. Asian Pac J Cancer Prev 2003; 4: 7-14.
130. Sengupta SR, Das NK, Datta PK. Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol 2008; 74: 559-70.
131. Knobeloch LM, Zierold KM, Anderson HA. Association of arseniccontaminated drinking-water with prevalence of skin cancer in Wisconsin's Fox River Valley. J Health Popul Nutr 2006; 24: 206-13.
132. Hughes MF. Arsenic toxicity and potential mechanisms of action. Toxicol Lett 2002; 133: 1-16.
133. Warren JB, Loi RK, Coughlan ML. Involvement of nitric oxide synthase in the delayed vasodilator response to ultraviolet light irradiation of rat skin in vivo. Br J Pharmacol 1993; 109: 802-6.
134. Hruza LL, Pentland AP. Mechanisms of UV-induced inflammation. J Invest Dermatol 1993; 100: 35S-41S.
135. Grewe M, Trefzer U, Ballhorn A, Gyufko K, Henninger H, Krutmann J. Analysis of the mechanism of ultraviolet (UV) B radiation-induced prostaglandin E2 synthesis by human epidermoid carcinoma cells. J Invest Dermatol 1993; 101: 528-31.
136. Lee JL, Mukhtar H, Bickers DR, Kopelovich L, Athar M. Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol Appl Pharmacol 2003; 192: 294-306.
137. Sluyter R, Halliday GM. Enhanced tumor growth in UV-irradiated skin is associated with an influx of inflammatory cells into the epidermis. Carcinogenesis 2000; 21: 1801-7.
138. Sluyter R, Halliday GM. Infiltration by inflammatory cells required for solar-simulated ultraviolet radiation enhancement of skin tumor growth. Cancer Immunol Immunother 2001; 50: 151-6.
139. Venugopal SS, Murrell DF. Treatment of skin cancers in epidermolysis bullosa. Dermatol Clin 2010; 28: 283-7.
140. Darlington S, Williams G, Neale R, Frost C, Green A. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol 2003; 139: 451-5.
141. van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006; 15: 2546-8.
142. Neale R, Williams G, Green A. Application patterns among participants randomized to daily sunscreen use in a skin cancer prevention trial. Arch Dermatol 2002; 138: 1319-25.
143. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-93.
144. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6: 949-56.
145. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7.
146. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-8.
147. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999; 140: 656-60.
148. George R, WeightmanW, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43: 269-73.
149. Nijsten TEC, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49: 644-50.
150. DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001; 45: S176-82.
151. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002; 76: 73-80.
152. Muller-Decker K, Reinerth G, Krieg P, et al. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 1999; 82: 648-56.
153. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-27.
154. Rothwell PM, Price JF, Fowkes FGR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-12.
155. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-601.
156. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, openlabel assessment of the treatment of actinic keratosis with 30% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004; 3: 401-7.
157. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 25% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-13.
158. Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005; 53: 966-72.
159. Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010; 102: 1835-44.
160. Meyskens FL Jr, McLaren CE. Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? J Natl Cancer Inst 2010; 102: 1815-7.
161. Gilmour SK. Polyamines and nonmelanoma skin cancer. Toxicol Appl Pharmacol 2007; 224: 249-56.
162. Alberts DS, Dorr RT, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000; 9: 1281-6.
163. Bailey HH, Kim K, Verma AK, et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}- difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila) 2010; 3: 35-47.
164. Barthelman M, Chen W, Gensler HL, Huang C, Dong Z, Bowden GT. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 1998; 58: 711-6.
165. Hakim IA, Harris RB, Ritenbaugh C. Citrus peel use is associated with reduced risk of squamous cell carcinoma of the skin. Nutr Cancer 2000; 37: 161-8.
166. Nichols JA, Katiyar SK. Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res 2010; 302: 71-83.
167. Katiyar SK, Agarwal R, Wood GS, Mukhtar H. Inhibition of 12-Otetradecanoylphorbol- 13-acetate-caused tumor promotion in 7, 12-dimethylbenz[a]anthracene-initiated SENCAR mouse skin by a polyphenolic fraction isolated from green tea. Cancer Res 1992; 52: 6890-7.
168. Agarwal R, Katiyar SK, Khan SG, Mukhtar H. Protection against ultraviolet B radiation-induced effects in the skin of SKH-1 hairless mice by a polyphenolic fraction isolated from green tea. Photochem Photobiol 1993; 58: 695-700.
169. Katiyar SK. Skin photoprotection by green tea: antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3: 234-42.
170. Friedmann AC, Halliday GM, Barnetson RS, et al. The topical isoflavonoid NV-07alpha reduces solar-simulated UV-induced suppression of Mantoux reactions in humans. Photochem Photobiol 2004; 80: 416-21.
171. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7: 684-700.
172. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252-61.
173. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. (Erratum appears in Am J Clin Nutr 2008;87:794.). Am J Clin Nutr 2007; 85: 1586-91.
174. Tang JY, Parimi N, Wu A, et al. Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control 2010; 21: 387-91.
175. Damian DL, Kim YJ, Dixon KM, Halliday GM, Javeri A, Mason RS. Topical calcitriol protects from UV-induced genetic damage but suppresses cutaneous immunity in humans. Exp Dermatol 2010; 19: e23-e30.
176. Dixon KM, Norman AW, Sequeira VB, et al. 1alpha, 25(OH)2-vitamin D and a nongenomic vitamin D analogue inhibit ultraviolet radiationinduced skin carcinogenesis. Cancer Prev Res (Phila) 2011; 4: 1485-94.
177. Sousa FG, Matuo R, Soares DG, et al. PARPs and the DNA damage response. Carcinogenesis 2012; 33: 1433-40.
178. Damian DL, Patterson CRS, Stapelberg M, Park J, Barnetson RS, Halliday GM. Ultraviolet radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol 2008; 128: 447-54.
179. Yiasemides E, Sivapirabu G, Halliday GM, Park J, Damian DL. Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogen 2009; 30: 101-5.
180. Sivapirabu G, Yiasemides E, Halliday GM, Park J, Damian DL. Topical nicotinamide modulates cellular energy metabolism and provides broadspectrum protection against ultraviolet radiation-induced immunosuppression in humans. Br J Dermatol 2009; 161: 1357-64.
181. Surjana D, Halliday GM, Martin AJ, Moloney FJ, Damian DL. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 2012; 132: 1497-500.
182. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. Diabetologia 2000; 43: 1337-45.
183. Niren NM. Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review. Cutis 2006; 77: 11-6.
184. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115: 273-7.